Back to News Items

August 2012 : New Article: Sitagliptin Phosphate Set to Soar in Sales

Main bullet points:

  • On June 26, 2012 Evaluate Pharma revealed it's World Preview 2018 projections, which touted Sitagliptin Phosphate as a future blockbuster drug.
  • Sitagliptin Phosphate (Januvia) is estimated to glean 10 billion dollars in sales annually by 2018.
  • The patent for Januvia expires on April 24, 2017.
  • By the year 2050 the CDC estimates that nearly one out of every three adults in the United States could have Type 2 Diabetes.
  • Genetic susceptibility is also being considered by researchers who are studying the development of Type 2 Diabetes in specific populations and groups worldwide, like the Israeli Circassians.
  • Promising data was reported at the 61st Annual Scientific Meeting of the Gerontological Society of America, indicating sitagliptin to be safe for the often hard to treat elderly population with Type 2 Diabetes. Hypoglycemia, which is a typical concern for the elderly population did not occur at all in studies documented.
  • Clinical development and trials of Sitagliptin Phosphate is strong, robust and continuing.



Dun and Bradstreet